Research Studies Validate Superiority of Lupus Test for Clinical Decision-Making and Patient Management
Two studies have validated the clinical performance of the AVISE® Lupus test in patients with probable systemic lupus erythematosus (SLE) and demonstrated the superior clinical utility of the test compared to standard diagnostic testing. The research supporting the AVISE Lupus test published in Lupus Science & Medicine and Arthritis & Rheumatology. Collectively, the studies further validate that the information contained in the AVISE Lupus test positively impacts physician clinical decision-making and demonstrated the patented test and algorithm helped predict those people with early signs of SLE that are likely to transition to classifiable SLE according to American College of Rheumatology (ACR) criteria.
A 10-marker diagnostic blood test, the AVISE Lupus test is designed to help healthcare providers diagnose lupus and other autoimmune diseases. The test contains Cell-Bound Complement Activation Products (CB-CAPs) and patented SLE biomarkers, which offer greater sensitivity than other tests.
The Lupus Foundation of America conducted early research that helped the development of the AVISE Lupus test. Development of tests that will help improve the ability to diagnose and manage people suspected of lupus is important. Learn more.